Tuesday 26th April 2011 |
Text too small? |
A company working on a cure for hepatitis C has been forced to close because of South Canterbury Finance's (SCF) receivership.
Blenheim-based pharmaceutical company Biocorp owed SCF $13.6 million and was placed into receivership by SCF's receivers on February 1, The Timaru Herald reported.
Former SCF chairman Allan Hubbard, who had a 10% shareholding in Biocorp, earlier told the National Business Review it was working on a cure for hepatitis C.
It had planned to hold clinical trials in Egypt but political unrest meant they could not go ahead.
Biocorp's receivers Jeremy Morley and John Fisk said it was placed into receivership because it defaulted on repayments to SCF.
The company owned property including land, coolstore industrial buildings and various plant and equipment at the Cloudy Bay business park in Blenheim.
SCF was placed in receivership last year after it failed to find an equity partner to shore up the company and $1.6 billion was paid out under the Government guarantee scheme.
NZPA
No comments yet
AGL - Change in Senior Management
Devon Funds Morning Note - 01 May 2024
Rick Christie to step-aside as a non-executive director
CHI - New customer contract to upgrade Marsden Point
Synlait announces changes to Board of Directors
May 1st Morning Report
Devon Funds Morning Note - 30 April 2024
New Rural Advocacy Hub to be launched at Fieldays 2024
Serko signs five-year partnership renewal with Booking.com
NPH - 2024 Half Year Results Announcement Date